ID   NEUR2_HUMAN             Reviewed;         380 AA.
AC   Q9Y3R4; Q3KNW4; Q6NTB4;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   10-MAY-2017, entry version 142.
DE   RecName: Full=Sialidase-2;
DE            EC=3.2.1.18;
DE   AltName: Full=Cytosolic sialidase;
DE   AltName: Full=N-acetyl-alpha-neuraminidase 2;
GN   Name=NEU2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND VARIANT
RP   ASN-168.
RX   PubMed=10191093; DOI=10.1006/geno.1999.5749;
RA   Monti E., Preti A., Rossi E., Ballabio A., Borsani G.;
RT   "Cloning and characterization of NEU2, a human gene homologous to
RT   rodent soluble sialidases.";
RL   Genomics 57:137-143(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-168.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=14613940; DOI=10.1074/jbc.M308381200;
RA   Tringali C., Papini N., Fusi P., Croci G., Borsani G., Preti A.,
RA   Tortora P., Tettamanti G., Venerando B., Monti E.;
RT   "Properties of recombinant human cytosolic sialidase HsNEU2. The
RT   enzyme hydrolyzes monomerically dispersed GM1 ganglioside molecules.";
RL   J. Biol. Chem. 279:3169-3179(2004).
RN   [6]
RP   CATALYTIC ACTIVITY, FUNCTION, ACTIVE SITE, AND MUTAGENESIS OF ASP-46;
RP   GLU-218 AND GLN-270.
RX   PubMed=22228546; DOI=10.1002/prot.24013;
RA   Mozzi A., Mazzacuva P., Zampella G., Forcella M.E., Fusi P.A.,
RA   Monti E.;
RT   "Molecular insight into substrate recognition by human cytosolic
RT   sialidase NEU2.";
RL   Proteins 80:1123-1132(2012).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.49 ANGSTROMS) IN COMPLEX WITH THE INHIBITOR
RP   2-DEOXY-2,3-DEHYDRO-N-ACETYLNEURAMINIC ACID.
RX   PubMed=15501818; DOI=10.1074/jbc.M411506200;
RA   Chavas L.M.G., Tringali C., Fusi P., Venerando B., Tettamanti G.,
RA   Kato R., Monti E., Wakatsuki S.;
RT   "Crystal structure of the human cytosolic sialidase Neu2. Evidence for
RT   the dynamic nature of substrate recognition.";
RL   J. Biol. Chem. 280:469-475(2005).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) IN COMPLEX WITH SUBSTRATE
RP   ANALOG, AND ACTIVE SITE.
RA   Buchini S., Gallat F.X., Greig I.R., Kim J.H., Wakatsuki S.,
RA   Withers S.G.;
RT   "Tuning mechanism-based inactivators of neuraminidases: mechanistic
RT   and structural insights.";
RL   Submitted (NOV-2013) to the PDB data bank.
RN   [9]
RP   CHARACTERIZATION OF VARIANT GLN-41.
RX   PubMed=17426694; DOI=10.1038/cr.2007.27;
RA   Li C.-Y., Yu Q., Ye Z.-Q., Sun Y., He Q., Li X.-M., Zhang W., Luo J.,
RA   Gu X., Zheng X., Wei L.;
RT   "A nonsynonymous SNP in human cytosolic sialidase in a small Asian
RT   population results in reduced enzyme activity: potential link with
RT   severe adverse reactions to oseltamivir.";
RL   Cell Res. 17:357-362(2007).
CC   -!- FUNCTION: Catalyzes the removal of sialic acid (N-acetylneuraminic
CC       acid) moities from glycoproteins, oligosaccharides and
CC       gangliosides. {ECO:0000269|PubMed:14613940,
CC       ECO:0000269|PubMed:22228546}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of alpha-(2->3)-, alpha-(2->6)-,
CC       alpha-(2->8)- glycosidic linkages of terminal sialic acid residues
CC       in oligosaccharides, glycoproteins, glycolipids, colominic acid
CC       and synthetic substrates. {ECO:0000269|PubMed:14613940,
CC       ECO:0000269|PubMed:22228546}.
CC   -!- INTERACTION:
CC       Q7Z3S9:NOTCH2NL; NbExp=6; IntAct=EBI-10327976, EBI-945833;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in skeletal muscle, fetal liver and
CC       embryonic carcinoma cell line NT2-D1.
CC       {ECO:0000269|PubMed:10191093}.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 33 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y16535; CAB41449.1; -; Genomic_DNA.
DR   EMBL; AC106876; AAY24360.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW71028.1; -; Genomic_DNA.
DR   EMBL; BC069151; AAH69151.1; -; mRNA.
DR   EMBL; BC107053; AAI07054.1; -; mRNA.
DR   CCDS; CCDS2501.1; -.
DR   RefSeq; NP_005374.2; NM_005383.2.
DR   UniGene; Hs.532681; -.
DR   PDB; 1SNT; X-ray; 1.75 A; A=1-380.
DR   PDB; 1SO7; X-ray; 1.49 A; A=1-380.
DR   PDB; 1VCU; X-ray; 2.85 A; A/B=1-380.
DR   PDB; 2F0Z; X-ray; 2.80 A; A=1-380.
DR   PDB; 2F10; X-ray; 2.90 A; A=1-380.
DR   PDB; 2F11; X-ray; 2.57 A; A=1-380.
DR   PDB; 2F12; X-ray; 2.27 A; A=1-380.
DR   PDB; 2F13; X-ray; 2.26 A; A=1-380.
DR   PDB; 2F24; X-ray; 1.76 A; A=1-380.
DR   PDB; 2F25; X-ray; 1.95 A; A/B=1-380.
DR   PDB; 2F26; X-ray; 1.58 A; A=1-380.
DR   PDB; 2F27; X-ray; 2.15 A; A/B=1-380.
DR   PDB; 2F28; X-ray; 1.67 A; A=1-380.
DR   PDB; 2F29; X-ray; 2.92 A; A/B=1-380.
DR   PDB; 4NC5; X-ray; 2.51 A; A=1-380.
DR   PDB; 4NCS; X-ray; 2.20 A; A=1-380.
DR   PDBsum; 1SNT; -.
DR   PDBsum; 1SO7; -.
DR   PDBsum; 1VCU; -.
DR   PDBsum; 2F0Z; -.
DR   PDBsum; 2F10; -.
DR   PDBsum; 2F11; -.
DR   PDBsum; 2F12; -.
DR   PDBsum; 2F13; -.
DR   PDBsum; 2F24; -.
DR   PDBsum; 2F25; -.
DR   PDBsum; 2F26; -.
DR   PDBsum; 2F27; -.
DR   PDBsum; 2F28; -.
DR   PDBsum; 2F29; -.
DR   PDBsum; 4NC5; -.
DR   PDBsum; 4NCS; -.
DR   ProteinModelPortal; Q9Y3R4; -.
DR   SMR; Q9Y3R4; -.
DR   BioGrid; 110832; 21.
DR   IntAct; Q9Y3R4; 2.
DR   STRING; 9606.ENSP00000233840; -.
DR   BindingDB; Q9Y3R4; -.
DR   ChEMBL; CHEMBL3200; -.
DR   DrugBank; DB00198; Oseltamivir.
DR   DrugBank; DB00558; Zanamivir.
DR   SwissLipids; SLP:000001360; -.
DR   CAZy; GH33; Glycoside Hydrolase Family 33.
DR   iPTMnet; Q9Y3R4; -.
DR   PhosphoSitePlus; Q9Y3R4; -.
DR   BioMuta; NEU2; -.
DR   DMDM; 229462907; -.
DR   EPD; Q9Y3R4; -.
DR   PaxDb; Q9Y3R4; -.
DR   PeptideAtlas; Q9Y3R4; -.
DR   PRIDE; Q9Y3R4; -.
DR   Ensembl; ENST00000233840; ENSP00000233840; ENSG00000115488.
DR   GeneID; 4759; -.
DR   KEGG; hsa:4759; -.
DR   UCSC; uc010zmn.2; human.
DR   CTD; 4759; -.
DR   GeneCards; NEU2; -.
DR   H-InvDB; HIX0029978; -.
DR   HGNC; HGNC:7759; NEU2.
DR   HPA; CAB022336; -.
DR   MIM; 605528; gene.
DR   neXtProt; NX_Q9Y3R4; -.
DR   OpenTargets; ENSG00000115488; -.
DR   PharmGKB; PA31561; -.
DR   eggNOG; ENOG410IFVF; Eukaryota.
DR   eggNOG; ENOG410Y74Z; LUCA.
DR   GeneTree; ENSGT00390000011171; -.
DR   HOGENOM; HOG000233778; -.
DR   HOVERGEN; HBG052608; -.
DR   InParanoid; Q9Y3R4; -.
DR   KO; K12357; -.
DR   OMA; QDTLECQ; -.
DR   OrthoDB; EOG091G08BI; -.
DR   PhylomeDB; Q9Y3R4; -.
DR   TreeFam; TF331063; -.
DR   BRENDA; 3.2.1.18; 2681.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-4085001; Sialic acid metabolism.
DR   SABIO-RK; Q9Y3R4; -.
DR   EvolutionaryTrace; Q9Y3R4; -.
DR   GeneWiki; NEU2; -.
DR   GenomeRNAi; 4759; -.
DR   PRO; PR:Q9Y3R4; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000115488; -.
DR   CleanEx; HS_NEU2; -.
DR   Genevisible; Q9Y3R4; HS.
DR   GO; GO:1902494; C:catalytic complex; IDA:CAFA.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0052794; F:exo-alpha-(2->3)-sialidase activity; IDA:UniProtKB.
DR   GO; GO:0052795; F:exo-alpha-(2->6)-sialidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052796; F:exo-alpha-(2->8)-sialidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004308; F:exo-alpha-sialidase activity; IDA:CAFA.
DR   GO; GO:0051692; P:cellular oligosaccharide catabolic process; IDA:CAFA.
DR   GO; GO:0006689; P:ganglioside catabolic process; IDA:UniProtKB.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0009313; P:oligosaccharide catabolic process; IDA:UniProtKB.
DR   InterPro; IPR026945; Sialidase-2.
DR   InterPro; IPR026856; Sialidase_fam.
DR   InterPro; IPR011040; Sialidases.
DR   PANTHER; PTHR10628; PTHR10628; 1.
DR   PANTHER; PTHR10628:SF27; PTHR10628:SF27; 1.
DR   Pfam; PF13088; BNR_2; 1.
DR   SUPFAM; SSF50939; SSF50939; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Carbohydrate metabolism; Complete proteome; Cytoplasm;
KW   Glycosidase; Hydrolase; Lipid degradation; Lipid metabolism;
KW   Polymorphism; Reference proteome; Repeat.
FT   CHAIN         1    380       Sialidase-2.
FT                                /FTId=PRO_0000208899.
FT   REPEAT      127    138       BNR 1.
FT   REPEAT      197    208       BNR 2.
FT   MOTIF        20     23       FRIP motif.
FT   ACT_SITE     46     46       Proton acceptor.
FT   ACT_SITE    334    334       Nucleophile.
FT   ACT_SITE    355    355       {ECO:0000255}.
FT   BINDING      21     21       Substrate.
FT   BINDING      41     41       Substrate.
FT   BINDING     179    179       Substrate.
FT   BINDING     181    181       Substrate.
FT   BINDING     218    218       Substrate.
FT   BINDING     237    237       Substrate.
FT   BINDING     304    304       Substrate.
FT   VARIANT      11     11       S -> R (in dbSNP:rs2233384).
FT                                /FTId=VAR_024461.
FT   VARIANT      41     41       R -> Q (reduced activity; increased
FT                                sensitivity to inhibition by oseltamivir
FT                                carboxylate; dbSNP:rs2233385).
FT                                {ECO:0000269|PubMed:17426694}.
FT                                /FTId=VAR_024462.
FT   VARIANT     145    145       A -> T (in dbSNP:rs2233390).
FT                                /FTId=VAR_049204.
FT   VARIANT     168    168       H -> N (in dbSNP:rs2233391).
FT                                {ECO:0000269|PubMed:10191093,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_055311.
FT   VARIANT     182    182       R -> Q (in dbSNP:rs2233393).
FT                                /FTId=VAR_055312.
FT   MUTAGEN      46     46       D->A: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:22228546}.
FT   MUTAGEN     218    218       E->A,Q: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:22228546}.
FT   MUTAGEN     270    270       Q->E: No effect on enzyme activity.
FT                                {ECO:0000269|PubMed:22228546}.
FT   STRAND        7     14       {ECO:0000244|PDB:1SO7}.
FT   STRAND       16     18       {ECO:0000244|PDB:2F0Z}.
FT   STRAND       20     28       {ECO:0000244|PDB:1SO7}.
FT   TURN         29     32       {ECO:0000244|PDB:1SO7}.
FT   STRAND       33     40       {ECO:0000244|PDB:1SO7}.
FT   HELIX        46     48       {ECO:0000244|PDB:2F25}.
FT   STRAND       51     60       {ECO:0000244|PDB:1SO7}.
FT   TURN         61     64       {ECO:0000244|PDB:1SO7}.
FT   STRAND       65     68       {ECO:0000244|PDB:1SO7}.
FT   STRAND       75     77       {ECO:0000244|PDB:2F10}.
FT   STRAND       82     91       {ECO:0000244|PDB:1SO7}.
FT   TURN         93     95       {ECO:0000244|PDB:1SO7}.
FT   STRAND       98    108       {ECO:0000244|PDB:1SO7}.
FT   HELIX       111    115       {ECO:0000244|PDB:1SO7}.
FT   STRAND      116    118       {ECO:0000244|PDB:2F12}.
FT   STRAND      123    131       {ECO:0000244|PDB:1SO7}.
FT   HELIX       143    147       {ECO:0000244|PDB:1SO7}.
FT   HELIX       148    153       {ECO:0000244|PDB:1SO7}.
FT   STRAND      154    159       {ECO:0000244|PDB:1SO7}.
FT   STRAND      174    182       {ECO:0000244|PDB:1SO7}.
FT   STRAND      185    188       {ECO:0000244|PDB:1SO7}.
FT   STRAND      191    201       {ECO:0000244|PDB:1SO7}.
FT   STRAND      213    225       {ECO:0000244|PDB:1SO7}.
FT   STRAND      230    250       {ECO:0000244|PDB:1SO7}.
FT   STRAND      259    265       {ECO:0000244|PDB:1SO7}.
FT   TURN        268    270       {ECO:0000244|PDB:1SO7}.
FT   STRAND      275    280       {ECO:0000244|PDB:1SO7}.
FT   STRAND      290    298       {ECO:0000244|PDB:1SO7}.
FT   STRAND      301    314       {ECO:0000244|PDB:1SO7}.
FT   HELIX       318    320       {ECO:0000244|PDB:1SO7}.
FT   STRAND      325    342       {ECO:0000244|PDB:1SO7}.
FT   STRAND      346    356       {ECO:0000244|PDB:1SO7}.
FT   TURN        357    360       {ECO:0000244|PDB:1SO7}.
FT   STRAND      361    368       {ECO:0000244|PDB:1SO7}.
FT   HELIX       369    372       {ECO:0000244|PDB:1SO7}.
FT   HELIX       374    376       {ECO:0000244|PDB:1SO7}.
SQ   SEQUENCE   380 AA;  42254 MW;  AD7B08C478F4D0D9 CRC64;
     MASLPVLQKE SVFQSGAHAY RIPALLYLPG QQSLLAFAEQ RASKKDEHAE LIVLRRGDYD
     APTHQVQWQA QEVVAQARLD GHRSMNPCPL YDAQTGTLFL FFIAIPGQVT EQQQLQTRAN
     VTRLCQVTST DHGRTWSSPR DLTDAAIGPA YREWSTFAVG PGHCLQLHDR ARSLVVPAYA
     YRKLHPIQRP IPSAFCFLSH DHGRTWARGH FVAQDTLECQ VAEVETGEQR VVTLNARSHL
     RARVQAQSTN DGLDFQESQL VKKLVEPPPQ GCQGSVISFP SPRSGPGSPA QWLLYTHPTH
     SWQRADLGAY LNPRPPAPEA WSEPVLLAKG SCAYSDLQSM GTGPDGSPLF GCLYEANDYE
     EIVFLMFTLK QAFPAEYLPQ
//
